UPB
NASDAQ · Biotechnology
Upstream Bio Inc
$8.99
-0.21 (-2.23%)
Open$9.14
Previous Close$9.19
Day High$9.14
Day Low$8.69
52W High$33.68
52W Low$7.25
Volume—
Avg Volume424.4K
Market Cap488.96M
P/E Ratio—
EPS$-2.66
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+174.7% upside
Current
$8.99
$8.99
Target
$24.68
$24.68
$18.50
$24.68 avg
$35.72
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.88M | 2.17M | 177.59M |
| Net Income | -144,953,061 | -98,059,046 | -3,219,143 |
| Profit Margin | -5,026.0% | -4,774.7% | -1.8% |
| EBITDA | -161,877,675 | -115,592,146 | -5,179,349 |
| Free Cash Flow | — | — | -3,332,995 |
| Rev Growth | +33.0% | +33.0% | -5.8% |
| Debt/Equity | — | — | 0.62 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |